Assessing Ascendis Pharma (ASND) Valuation After Positive COACH Trial Growth And Proportionality Results

Simply Wall St.

01/17

Ascendis Pharma (NasdaqGS:ASND) is back in focus after releasing Week 52 topline data from its Phase 2 COACH trial, in which once weekly TransCon CNP and TransCon hGH combination therapy produced ...

网页链接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2604918281"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2604918281\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2604918281?lang=zh_TW&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-01-17 00:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2604918281","market":"hk","top_or_hot":-1,"title":"Assessing Ascendis Pharma (ASND) Valuation After Positive COACH Trial Growth And Proportionality Results","media":"Simply Wall St.","content":"<div>\n<p>Ascendis Pharma (NasdaqGS:ASND) is back in focus after releasing Week 52 topline data from its Phase 2 COACH trial, in which once weekly TransCon CNP and TransCon hGH combination therapy produced ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-asnd/ascendis-pharma/news/assessing-ascendis-pharma-asnd-valuation-after-positive-coac-1\">网页链接</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Ascendis Pharma (ASND) Valuation After Positive COACH Trial Growth And Proportionality Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Ascendis Pharma (ASND) Valuation After Positive COACH Trial Growth And Proportionality Results\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Simply Wall St.</strong><span class=\"h-time small\">2026-01-17 00:36</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>Ascendis Pharma (NasdaqGS:ASND) is back in focus after releasing Week 52 topline data from its Phase 2 COACH trial, in which once weekly TransCon CNP and TransCon hGH combination therapy produced ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-asnd/ascendis-pharma/news/assessing-ascendis-pharma-asnd-valuation-after-positive-coac-1\">网页链接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-asnd/ascendis-pharma/news/assessing-ascendis-pharma-asnd-valuation-after-positive-coac-1\">Simply Wall St.</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0320765992.SGD","symbol_name":"FTIF - Franklin Biotechnology Discovery A Acc SGD","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-asnd/ascendis-pharma/news/assessing-ascendis-pharma-asnd-valuation-after-positive-coac-1","article_id":"2604918281","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-asnd/ascendis-pharma/news/assessing-ascendis-pharma-asnd-valuation-after-positive-coac-1","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2604918281","pubTimestamp":1768581387,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Ascendis Pharma (NasdaqGS:ASND) is back in focus after releasing Week 52 topline data from its Phase 2 COACH trial, in which once weekly TransCon CNP and TransCon hGH combination therapy produced durable growth and proportionality benefits.\nSee our latest analysis for Ascendis Pharma.\nInvestors appear to be weighing the fresh COACH trial readout against Ascendis Pharma’s recent share price performance. The stock is at US$215.04 after a 3.0% 7 day share price gain and a 63.4% 1 year total...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","ASND":"Ascendis Pharma A/S"},"translate_title":"在积极的COACH试验增长和比例结果后评估Ascendis Pharma(ASND)估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ASND":1.5},"content_text":"Ascendis Pharma (NasdaqGS:ASND) is back in focus after releasing Week 52 topline data from its Phase 2 COACH trial, in which once weekly TransCon CNP and TransCon hGH combination therapy produced durable growth and proportionality benefits. See our latest analysis for Ascendis Pharma. Investors appear to be weighing the fresh COACH trial readout against Ascendis Pharma’s recent share price performance. The stock is at US$215.04 after a 3.0% 7 day share price gain and a 63.4% 1 year total shareholder return, suggesting momentum has been building over the longer term. If rare disease data like this has your attention, it could be a good moment to see what else is on the move across healthcare stocks. With Ascendis Pharma posting a 63.4% 1 year total return and trading at US$215.04, plus an indicated intrinsic discount of roughly 77%, you have to ask: is there still a buying opportunity here, or is the market already pricing in future growth? AdvertisementMost Popular Narrative: 17.4% Undervalued Against the last close of US$215.04, the most followed narrative pegs Ascendis Pharma's fair value closer to US$260, framing today’s price as discounted.  Regulatory progress and pipeline advancement, such as the priority review for TransCon CNP in achondroplasia and positive combination trial results, are paving the way for new blockbuster therapies and potential multi-billion EUR peak sales opportunities, enhancing future revenue growth and reducing revenue concentration risk.  Read the complete narrative. Curious what earnings, revenue growth, and margin profile would support that higher fair value? The narrative leans on ambitious compounding, richer profitability, and a future P/E that sits above the broader biotech group. The full breakdown shows how those pieces fit together. Result: Fair Value of $260 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this upbeat narrative still leans heavily on YORVIPATH and SKYTROFA delivering as expected, while any regulatory or safety setbacks could quickly challenge those confidence assumptions. Find out about the key risks to this Ascendis Pharma narrative. Another View: Multiples Send a Different Signal The AI narrative and SWS model point to Ascendis Pharma trading roughly 77% below an implied fair value of US$929.57, which paints a clear undervaluation story. But if you look at pricing based on sales, the picture is more mixed and comes with very different implications. On P/S, Ascendis trades at 17.6x. That is higher than the US Biotechs industry average of 12.8x and slightly above the SWS fair ratio of 16.9x, yet still well below the peer average of 29.6x. So the stock screens expensive against the broader group, modestly rich versus the level the market could move towards, and cheaper than closer peers. For you, that sets up a simple question: is this a premium you are comfortable paying for the specific story here? See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:ASND P/S Ratio as at Jan 2026 Build Your Own Ascendis Pharma Narrative If you look at the numbers and reach a different conclusion, or simply prefer your own work, you can build a full Ascendis view yourself in minutes: Do it your way. A great starting point for your Ascendis Pharma research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision. Looking for more investment ideas? Before you move on, take a few minutes to scan fresh ideas with clear data behind them so you are not relying on one stock to carry your thesis.  Spot potential turnarounds early by checking out these 3539 penny stocks with strong financials that already back their stories with stronger balance sheets and fundamentals. Review structural shifts in technology by exploring these 24 AI penny stocks that connect artificial intelligence themes to real revenue and business models. Focus on price versus cash generation by using these 868 undervalued stocks based on cash flows to see which companies screens flag as trading below their cash flow metrics.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}